Corebridge Financial Inc. Sells 10,465 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Corebridge Financial Inc. lowered its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 205,099 shares of the biopharmaceutical company's stock after selling 10,465 shares during the quarter. Corebridge Financial Inc. owned 0.16% of Halozyme Therapeutics worth $9,806,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $21,838,000. Vanguard Group Inc. grew its stake in Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock worth $634,999,000 after buying an additional 386,618 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Halozyme Therapeutics by 698.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock worth $13,756,000 after buying an additional 251,711 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Halozyme Therapeutics by 60.0% in the fourth quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company's stock valued at $31,112,000 after acquiring an additional 243,940 shares during the last quarter. Finally, Boston Trust Walden Corp raised its holdings in shares of Halozyme Therapeutics by 28.0% in the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock valued at $41,790,000 after buying an additional 191,465 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 31,697 shares of company stock worth $1,754,451. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Down 0.0 %

Shares of HALO traded down $0.03 on Monday, hitting $63.81. The company's stock had a trading volume of 1,641,666 shares, compared to its average volume of 1,378,293. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm has a market capitalization of $7.88 billion, a price-to-earnings ratio of 18.60, a P/E/G ratio of 0.42 and a beta of 1.32. The firm's fifty day moving average price is $59.34 and its 200-day moving average price is $54.84. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

HALO has been the topic of a number of research analyst reports. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Benchmark restated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.